New hope for rare sarcoma? drug combo tested in 44 patients
NCT ID NCT03802071
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (doxorubicin) could help people with advanced soft tissue sarcoma that has spread or come back. The trial included 44 adults whose cancer could be measured and who were healthy enough for treatment. The main goal was to check safety and see if the combination works better than chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea